Michael Chiorean, MD
Gastroenterology · Issaquah, WANPI 1578527099
Payments from drug & device makers
Across 2,035 payments — averaging $1896.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.6M
- Pfizer$511K
- Takeda Pharmaceuticals U.S.A., Inc.$417K
- E.r. Squibb & Sons, L.L.C.$269K
- Eli Lilly$259K
- Janssen Research & Development, LLC$249K
- plus $596K from 28 others
Across 64 payments — averaging $1013.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$58K
- Eli Lilly$6K
- AbbVie$547
What the payments were for
- Consulting fees$171,00212%
- Speaking & faculty fees$1,064,54175%
- Travel & lodging$150,99111%
- Food & beverage$30,8042%
- Education$7,2801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 594 | $1,558,085 |
| Pfizer(2 entities) | 371 | $511,399 |
| Takeda Pharmaceuticals U.S.A., Inc. | 267 | $417,292 |
| E.r. Squibb & Sons, L.L.C. | 147 | $269,357 |
| Eli Lilly | 36 | $258,944 |
| Janssen Research & Development, LLC | 62 | $248,691 |
| Lilly USA, LLC | 157 | $127,935 |
| Johnson & Johnson | 130 | $98,209 |
| Janssen Scientific Affairs, LLC | 90 | $78,730 |
| Roche Products Limited | 57 | $68,200 |
| Bristol Myers Squibb | 48 | $56,706 |
| Covidien LP | 16 | $54,096 |
| Boehringer Ingelheim | 6 | $43,857 |
| Celltrion USA Inc. | 14 | $19,778 |
| Gilead | 2 | $16,743 |
| Whitehall International Inc | 3 | $11,375 |
| Merck | 10 | $8,582 |
| Amgen | 3 | $4,649 |
| Fresenius Kabi USA, LLC | 2 | $3,660 |
| Boehringer Ingelheim RCV GmbH & Co KG | 2 | $1,279 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,250 |
| GI Supply, Inc. | 1 | $300 |
| Medtronic | 1 | $198 |
| Laborie Medical Technologies Corp. | 1 | $190 |
| Aimmune Therapeutics, Inc. | 4 | $140 |
| Endogastric Solutions, Inc | 1 | $67 |
| 3-d Matrix, Inc. | 1 | $52 |
| Samsung HME America, Inc. | 1 | $50 |
| Organon | 2 | $37 |
| Genentech USA, Inc. | 1 | $35 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Capsovision, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,859,983 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 28 | $756,450 |
| XeljanzTofacitinib Citrate | 11 | $61,123 |
| CreonLipase/Protease/Amylase | 18 | $18,111 |
| Mesalamine | 47 | $9,006 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 29 | $1,819 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 72 | $1,242 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 71 | $1,141 |
| Mercaptopurine | 14 | $1,035 |
| Azathioprine | 14 | $733 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 27 | $613 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 24 | $373 |
| Omeprazole | 34 | $365 |
| Imipramine Hcl | 11 | $78 |
| Pantoprazole Sodium | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $98,209 | $756,45028 claims |
| PfizerXeljanz | $511,399 | $61,12311 claims |
| AbbVieCreon | $1,558,085 | $18,11118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 447 gastroenterology providers in Washington.
Other gastroenterology in Issaquah
- Kris KowdleySeattle$5.9M
- Scott LeeSeattle$3.7M
- Timothy ZismanSeattle$3.3M
- William HoldermanTacoma$3.1M
- James LordSeattle$1.9M
- Charles LandisSeattle$1.7M
- Robert WohlmanBellevue$1.5M
- Asma SiddiqueSeattle$1.3M
- Harold PreiksaitisSpokane$1M
- Karlee AuskSeattle$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.